The Journal of Practical Medicine >
Advances in immunological research on hematopoietic stem cell transplantation
Received date: 2024-07-18
Online published: 2025-03-20
Allogeneic hematopoietic stem cell transplantation （allo-HSCT） is a therapeutic approach that restores hematopoietic and immune functions in recipients through the infusion of allogeneic hematopoietic stem cells. It has evolved into an effective form of adoptive cellular immunotherapy， offering curative potential for various diseases， including malignant hematologic disorders， hematopoietic failure syndromes， congenital immunodeficiencies， and genetic metabolic disorders. Immunology plays a pivotal role in allo-HSCT， as post-transplant immunobiology is uniquely characterized by the potential for immune recognition and attack between donor and host cells. This review elucidates the distinctive features of immune reconstitution following allo-HSCT， examines the immunological underpinnings of graft-versus-host disease （GVHD） and the graft-versus-leukemia （GVL） effect， and evaluates how novel therapeutic strategies modulate these immune responses to improve the management of transplant-related complications and enhance patient outcomes. Additionally， the review addresses the challenges in balancing GVHD and GVL effects and outlines potential directions for future research.
Xingchi CHEN , Xiaoyu. ZHU . Advances in immunological research on hematopoietic stem cell transplantation[J]. The Journal of Practical Medicine, 2025 , 41(5) : 641 -647 . DOI: 10.3969/j.issn.1006-5725.2025.05.004
| 1 | ROMMELEY M， SPIES-WEISSHART B， SCHILLING K， et al. Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation［J］. J Cancer Res Clin Oncol， 2011， 137（9）： 1293-1300. doi:10.1007/s00432-011-0989-x |
| 2 | 朱小玉. 脐血移植基础与临床［M］. 合肥：中国科学技术大学出版社， 2024. |
| 3 | SHANG Q N， YU X X， XU Z L， et al. Expanded clinical-grade NK cells exhibit stronger effects than primary NK cells against HCMV infection［J］. Cell Mol Immunol， 2023， 20（8）： 895-907. doi:10.1038/s41423-023-01046-5 |
| 4 | DULPHY N， HAAS P， BUSSON M， et al. An unusual CD56（bright） CD16（low） NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation［J］. J Immunol， 2008， 181（3）： 2227-2237. doi:10.4049/jimmunol.181.3.2227 |
| 5 | SWIECKI M， COLONNA M. The multifaceted biology of plasmacytoid dendritic cells［J］. Nat Rev Immunol， 2015， 15（8）： 471-485. doi:10.1038/nri3865 |
| 6 | KLYUCHNIKOV E， ASENOVA S， KERN W， et al. Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia［J］. Leuk Lymphoma， 2010， 51（8）： 1450-1463. doi:10.3109/10428194.2010.496015 |
| 7 | FRY T J， MACKALL C L. Immune reconstitution following hematopoietic progenitor cell transplantation： challenges for the future［J］. Bone Marrow Transplant， 2005， 35 ： S53-S57. doi:10.1038/sj.bmt.1704848 |
| 8 | STERN L， MCGUIRE H， AVDIC S， et al. Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation［J］. Front Immunol， 2018， 9： 1672. doi:10.3389/fimmu.2018.01672 |
| 9 | CORDóN L， CHOR?O P， MARTíN-HERREROS B， et al. Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies［J］. Ann Hematol， 2024， 103（7）： 2475-2484. doi:10.1007/s00277-024-05758-0 |
| 10 | KLEIN A K， PATEL D D， GOODING M E， et al. T-Cell recovery in adults and children following umbilical cord blood transplantation［J］. Biol Blood Marrow Transplant， 2001， 7（8）： 454-466. doi:10.1016/s1083-8791(01)80013-6 |
| 11 | ABDEL-AZIM H， ELSHOURY A， MAHADEO K M， et al. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children： A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution［J］. Biol Blood Marrow Transplant， 2017， 23（9）： 1437-1446. doi:10.1016/j.bbmt.2017.05.005 |
| 12 | TOMBLYN M， YOUNG J A， HAAGENSON M D， et al. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype［J］. Biol Blood Marrow Transplant， 2010， 16（8）： 1155-1161. doi:10.1016/j.bbmt.2010.02.024 |
| 13 | MCQUEEN K L， DORIGHI K M， GUETHLEIN L A， et al. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched， sibling donor hematopoietic cell transplantation［J］. Hum Immunol， 2007， 68（5）： 309-323. doi:10.1016/j.humimm.2007.01.019 |
| 14 | WILLEMZE R， RODRIGUES C A， LABOPIN M， et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia［J］. Leukemia， 2009， 23（3）： 492-500. doi:10.1038/leu.2008.365 |
| 15 | MARMONT A M， HOROWITZ M M， GALE R P， et al. T-cell depletion of HLA-identical transplants in leukemia［J］. Blood， 1991， 78（8）： 2120-2130. doi:10.1182/blood.v78.8.2120.bloodjournal7882120 |
| 16 | BALLESTER O F， FANG T， RAPTIS A， et al. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma［J］. Bone Marrow Transplant， 2004， 34（5）： 419-423. doi:10.1038/sj.bmt.1704617 |
| 17 | SCHMID C， LABOPIN M， NAGLER A， et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia： a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party［J］. J Clin Oncol， 2007， 25（31）： 4938-4945. doi:10.1200/jco.2007.11.6053 |
| 18 | DEVILLIER R， GALIMARD J E， BLAISE D， et al. Peripheral blood stem cell versus bone marrow graft for patients ≥60?years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission： An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation［J］. Am J Hematol， 2024， 99（7）： 1250-1256. doi:10.1002/ajh.27343 |
| 19 | ZHU X， TANG B， SUN Z. Umbilical cord blood transplantation： Still growing and improving［J］. Stem Cells Transl Med， 2021， 10（Suppl 2）： S62-S74. doi:10.1002/sctm.20-0495 |
| 20 | 中华医学会血液学分会造血干细胞应用学组. 慢性移植物抗宿主病（cGVHD）诊断与治疗中国专家共识（2021年版） ［J］. 中华血液学杂志， 2021， 42（4）： 265-275. |
| 21 | ZEISER R， POLVERELLI N， RAM R， et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease［J］. N Engl J Med， 2021， 385（3）： 228-238. doi:10.1056/nejmoa2033122 |
| 22 | MAXIMOVA N， NISTICò D， RICCIO G， et al. Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children： A Prospective， Single-Center Study［J］. Cancers （Basel）， 2023， 15（14）：3605. doi:10.3390/cancers15143605 |
| 23 | KENNEDY G A， TEY S K， BUIZEN L， et al. A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis［J］. Blood， 2021， 137（14）： 1970-1979. doi:10.1182/blood.2020009050 |
| 24 | PIDALA J A， KIM J， KALOS D， et al. Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease： A multicenter real-world analysis［J］. Blood Adv， 2024.doi： 10.1182/bloodadvances.2024014374 . |
| 25 | YAO S， HE L， SUOLITIKEN D， et al. Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis： Yes or no？［J］. Blood， 2024， 144（20）： 2107-2120. doi:10.1182/blood.2023023287 |
| 26 | XUAN L， WANG Y， YANG K， et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia： Long-term follow-up of an open-label， multicentre， randomised， phase 3 trial［J］. Lancet Haematol， 2023， 10（8）： e600-e611. doi:10.1016/s2352-3026(23)00117-5 |
| 27 | ZHANG Z， HASEGAWA Y， HASHIMOTO D， et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation［J］. Bone Marrow Transplant， 2022， 57（5）： 775-780. doi:10.1038/s41409-022-01619-4 |
| 28 | KENT A， SCHWARTZ M， MCMAHON C， et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse［J］. Bone Marrow Transplant， 2023， 58（8）： 849-854. doi:10.1038/s41409-023-01987-5 |
| 29 | GARCIA J S， KIM H T， BROCK J， et al. Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML： Results of a Phase 1 Study［J］. Blood， 2022， 140（）： 917-919. doi:10.1182/blood-2022-157611 |
| 30 | ORAN B， CHAMPLIN R E， THALL P F， et al. Phase II trial of venetoclax （Ven） in combination with azacitidine （AZA） as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation （SCT）［J］. Blood， 2022， 140（）： 10561-10562. doi:10.1182/blood-2022-159312 |
| 31 | LEE J B， KHAN D H， HURREN R， et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production［J］. Blood， 2021， 138（3）： 234-245. doi:10.1182/blood.2020009081 |
| 32 | WANG Y， HUANG B， LIANG T， et al. Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia［J］. Cell Rep Med， 2024， 5（6）： 101580. doi:10.1016/j.xcrm.2024.101580 |
| 33 | BADER C S， PAVLOVA A， LOWSKY R， et al. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD［J］. Blood Adv， 2024， 8（5）： 1105-1115. doi:10.1182/bloodadvances.2023011625 |
| 34 | RAMOS T L， BOLIVAR-WAGERS S， JIN S， et al. Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo［J］. Blood， 2023， 141（11）： 1337-1352. doi:10.1182/blood.2022018440 |
| 35 | HUANG R， CHEN T， WANG S， et al. Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant： An Open-Label Randomized Clinical Trial［J］. JAMA Oncol， 2024， 10（2）： 220-226. doi:10.1001/jamaoncol.2023.5757 |
| 36 | BEDNARSKI J J， ZIMMERMAN C， BERRIEN-ELLIOTT M M， et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant［J］. Blood， 2022， 139（11）： 1670-1683. doi:10.1182/blood.2021013972 |
| 37 | LEE K H， YOON S R， GONG J R， et al. The infusion of ex vivo， interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial［J］. Leukemia， 2023， 37（4）： 807-819. doi:10.1038/s41375-023-01849-5 |
| 38 | FISCHER K， VOELKL S， HEYMANN J， et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4（-）CD8- double-negative regulatory T cells［J］. Blood， 2005， 105（7）： 2828-2835. doi:10.1182/blood-2004-07-2583 |
| 39 | ZHANG Z X， MA Y， WANG H， et al. Double-negative T cells， activated by xenoantigen， lyse autologous B and T cells using a perforin/granzyme-dependent， Fas-Fas ligand-independent pathway［J］. J Immunol， 2006， 177（10）： 6920-6929. doi:10.4049/jimmunol.177.10.6920 |
| 40 | GAO J F， MCINTYRE M S， JUVET S C， et al. Regulation of antigen-expressing dendritic cells by double negative regulatory T cells［J］. Eur J Immunol， 2011， 41（9）： 2699-2708. doi:10.1002/eji.201141428 |
| 41 | PAN T， DING P， HUANG A， et al. Reconstitution of double-negative T cells after cord blood transplantation and its predictive value for acute graft-versus-host disease［J］. Chin Med J （Engl）， 2024， 137（10）： 1207-1217. doi:10.1097/cm9.0000000000002807 |
| 42 | VASIC D， LEE J B， LEUNG Y， et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities［J］. Sci Immunol， 2022， 7（70）： eabl3642. doi:10.1126/sciimmunol.abl3642 |
| 43 | TANG B， LEE J B， CHENG S， et al. Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation： A first-in-human phase I study［J］. Am J Hematol， 2022， 97（7）： E264-E267. doi:10.1002/ajh.26564 |
| 44 | GODDER K T， HENSLEE-DOWNEY P J， MEHTA J， et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation［J］. Bone Marrow Transplant， 2007， 39（12）： 751-757. doi:10.1038/sj.bmt.1705650 |
| 45 | MCGUIRK J P， ABHYANKAR S H， GOSWAMI T， et al. Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide （Haplo/Cy） By Infusion of Donor-Derived Expanded/Activated Gd T Cells： A Phase I Trial［J］. Blood， 2022， 140（）： 7464-7465. doi:10.1182/blood-2022-169819 |
| 46 | NEELAPU S S， STEVENS D A， HAMADANI M， et al. A Phase 1 Study of ADI-001： Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 （γδ） T Cells in Adults with B-Cell Malignancies［J］. Blood， 2022， 140（）： 4617-4619. doi:10.1182/blood-2022-157400 |
| 47 | JOHANNA I， STRAETEMANS T， HEIJHUURS S， et al. Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells［J］. J Immunother Cancer， 2019， 7（1）： 69. doi:10.1186/s40425-019-0558-4 |
| 48 | STRAETEMANS T， KIERKELS G J J， DOORN R， et al. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR［J］. Front Immunol， 2018， 9： 1062. doi:10.3389/fimmu.2018.01062 |
| 49 | KAWASE T， MATSUO K， KASHIWASE K， et al. HLA mismatch combinations associated with decreased risk of relapse： implications for the molecular mechanism［J］. Blood， 2009， 113（12）： 2851-2858. doi:10.1182/blood-2008-08-171934 |
| 50 | YABE T， AZUMA F， KASHIWASE K， et al. HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation［J］. Leukemia， 2018， 32（1）： 168-175. doi:10.1038/leu.2017.202 |
| 51 | ZHAO X Y， CHANG Y J， ZHAO X S， et al. Recipient expression of ligands for donor inhibitory KIRs enhances NK-cell function to control leukemic relapse after haploidentical transplantation［J］. Eur J Immunol， 2015， 45（8）： 2396-2408. doi:10.1002/eji.201445057 |
| 52 | SCOTT B L， PASQUINI M C， LOGAN B R， et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes［J］. J Clin Oncol， 2017， 35（11）： 1154-1161. doi:10.1200/jco.2016.70.7091 |
| 53 | GAO L， WEN Q， CHEN X， et al. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation： A multicenter randomized controlled study in southwest China［J］. Biol Blood Marrow Transplant， 2014， 20（12）： 1932-1939. doi:10.1016/j.bbmt.2014.08.001 |
| 54 | BLEAKLEY M， HEIMFELD S， LOEB K R， et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts［J］. J Clin Invest， 2015， 125（7）： 2677-2689. doi:10.1172/jci81229 |
| 55 | RUGGERI L， CAPANNI M， URBANI E， et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants［J］. Science， 2002， 295（5562）： 2097-2100. doi:10.1126/science.1068440 |
| 56 | MARTELLI M F， DI IANNI M， RUGGERI L， et al. "Designed" grafts for HLA-haploidentical stem cell transplantation［J］. Blood， 2014， 123（7）： 967-973. doi:10.1182/blood-2013-10-531764 |
/
| 〈 |
|
〉 |